Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kyntra Bio (KYNB) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to 502.88%.

  • Kyntra Bio's EBITDA Margin rose 382711000.0% to 502.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 262.36%, marking a year-over-year decrease of 729800.0%. This contributed to the annual value of 2089.11% for FY2024, which is 13995800.0% down from last year.
  • Per Kyntra Bio's latest filing, its EBITDA Margin stood at 502.88% for Q3 2025, which was up 382711000.0% from 894.07% recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's EBITDA Margin registered a high of 128.84% during Q4 2023, and its lowest value of 38773.98% during Q3 2024.
  • Over the past 5 years, Kyntra Bio's median EBITDA Margin value was 611.44% (recorded in 2023), while the average stood at 3405.52%.
  • As far as peak fluctuations go, Kyntra Bio's EBITDA Margin tumbled by -386158100bps in 2024, and later surged by 382711000bps in 2025.
  • Over the past 5 years, Kyntra Bio's EBITDA Margin (Quarter) stood at 817.51% in 2021, then skyrocketed by 76bps to 192.49% in 2022, then skyrocketed by 167bps to 128.84% in 2023, then crashed by -71bps to 36.99% in 2024, then crashed by -1460bps to 502.88% in 2025.
  • Its EBITDA Margin stands at 502.88% for Q3 2025, versus 894.07% for Q2 2025 and 828.89% for Q1 2025.